sterna biologicals Gmbh & Co KG - Product Pipeline Review - 2015
Global Markets Direct’s, ‘sterna biologicals Gmbh & Co KG - Product Pipeline Review - 2015’, provides an overview of the sterna biologicals Gmbh & Co KG’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of sterna biologicals Gmbh & Co KG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides brief overview of sterna biologicals Gmbh & Co KG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of sterna biologicals Gmbh & Co KG’s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the sterna biologicals Gmbh & Co KG’s pipeline products
Reasons to buy
- Evaluate sterna biologicals Gmbh & Co KG’s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of sterna biologicals Gmbh & Co KG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the sterna biologicals Gmbh & Co KG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of sterna biologicals Gmbh & Co KG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of sterna biologicals Gmbh & Co KG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of sterna biologicals Gmbh & Co KG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Our reports have been used by over 10K customers, including:
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 126.96.36.199) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 188.8.131.52) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It...
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 184.108.40.206) - Pipeline Review, H2 2018 Summary Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 220.127.116.11) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Bullous Pemphigoid Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Bullous Pemphigoid pipeline products. The Bullous Pemphigoid pipeline guide presents complete overview of drugs currently being...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Hidradenitis Suppurativa Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Hidradenitis Suppurativa pipeline products. The Hidradenitis Suppurativa pipeline guide presents complete overview of...
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018 Summary According to the recently published report ’Integrin Alpha V - Pipeline Review, H2 2018’; Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close...
Interleukin 1 (IL1) - Pipeline Review, H2 2018 Summary Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.